Gene editing therapeutics that prevent epileptic seizures - -------------------------------------------------------------project summary------ -------------------------------------------------------…
Active Grant Awarded
- Award ID
- R56NS146956
- Recipient
-
The University Of Texas Health Science Center At San Antonio UEI C3KXNLTAAY98
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $565,436
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 21% complete
- Place of performance
- San Antonio, TX 78229, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, through the National Institutes of Health's National Institute of Neurological Disorders and Stroke, awarded Grant R56NS146956 to The University of Texas Health Science Center at San Antonio on September 9, 2026, with $565,436 obligated. The award is funded under Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853).
The funded work is research on gene editing therapeutics to prevent epileptic seizures. The project targets the SCN8A gene, which encodes the Nav1.6 voltage-gated sodium channel, and proposes CRISPR-based gene editing as an alternative to antisense approaches that require repeated brain injections. The project summary identifies the central obstacle as delivery: CRISPR must reach the brain through non-viral vehicles, and lipid nanoparticles delivering mRNA to the brain are currently inefficient. The source's project summary is truncated at that point, so the specific aims and deliverables are not stated in the record provided.
The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2027. Place of performance is San Antonio, Texas 78229. The assistance type is Grant.
Description
Gene editing therapeutics that prevent epileptic seizures - -------------------------------------------------------------project summary------ ------------------------------------------------------- epilepsy is a common neurological disorder that affects approximately 50 million people worldwide and a third of these patients do not achieve adequate seizure control. Available drugs, and neurosurgical removal of large brain only ~50% of epilepsies can be controlled with currently- regions remains the only other alternative for patients with crippling epileptic seizures, resulting in profound loss of memory and cognitive function. The voltage-gated NA+ channel, NAV1.6 is encoded by the SCN8A gene, and is a particularly compelling therapeutic candidate for treating epileptic seizures and knock-down of the SCN8A gene in the mouse brain reduces seizures. However, current methods for knocking down SCN8A gene are based on antisense strategies, which are difficult to clinically implement because they require repeated injections into the brain. Gene editing of the SCN8A gene has great promise to address the above-mentioned concern and additionally can permit allele-specific inactivation of dominant pathogenic allele in heterozygotes. Indeed, editing of a pathogenic SCN8A allele specifically has already been accomplished via crispr, using AAV as a delivery vector and rescued heterozygous mice from epileptic seizures. However, AAV- mediated gene editing in the brain is problematic because of prolonged expression of CAS9 as well as its immunogenicity. There is consequently an urgent need to develop safe and efficient non-viral delivery vehicles that can deliver crispr to the brain. Among non-viral delivery strategies, lipid nanoparticles (LNPS) have great potential for delivering mrna to the brain because of their well-characterized clinical track record and their versatility. However, mrna delivery to the brain with LNPS is currently inefficient because of limited diffusion in the brain and low levels of endosomal disruption, and needs to be more efficient before IT can generate significant therapeutics effects. To address this critical need, we developed acid-degradable LNPS (termed ADP-LNPS), which are made with acid- degradable polyethylene glycol (peg) lipids and can transfect large volumes of brain tissue after an intracranial injection, because they tolerate high levels of pegylation without losing activity. Our preliminary results demonstrate that ADP-LNPS deliver CAS9 mrna to the brain with remarkable efficiency via an intracranial injection; ~5 times higher gene editing efficiency than standard LNPS in the mouse brain. We have demonstrated that a single intracranial injection of ADP-LNPS carrying CAS9 mrna/AI9 sgrna could induce gene editing ~30% of the total cells in the dentate gyrus (DG), a part of the hippocampus using AI9 reporter mice. Additionally, we demonstrated that ADP- LNPS carrying CAS9 mrna/SCN8A sgrna could reduce NAV1.6 expression levels by ~50% in 1/3 of the DG without a sign of toxicity. These exciting results demonstrate that ADP-LNPS have great potential as precision-medicine therapeutics for epilepsy. The central objectives of this proposal are (1) to develop new LNP variants based upon ADP-LNPS with improved diffusion and efficiency, and (2) to develop a new therapeutic strategy for treating epileptic seizures based upon local crispr/CAS9-mediated SCN8A gene editing in the mouse hippocampus using our newly developed LNP-mrna complexes. The central hypothesis is: intracerebral delivery of LNP-mrna complexes that carry CAS9 mrna and sgrna targeting the SCN8A gene can prevent/rescue mice from epileptic seizures. Specific aim 1. Increase the mouse brain gene editing efficiency of the ADP-LNPS specific aim 2. Reduce seizures by knocking down SCN8A in a chemically-induced mouse seizure model specific aim 3. Reduce seizures by knocking down the pathogenic SCN8A-N1768D allele in a mouse model of pediatric seizures the experiments in this proposal are significant because if S
Quick answers
Who received award R56NS146956?
R56NS146956 was awarded to The University Of Texas Health Science Center At San Antonio by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.
How much is award R56NS146956 worth?
$565,436 has been obligated on R56NS146956.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award